Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab Combined With Daratumumab in Primary Immune Thrombocytopenia
NCT07362199Phase 2Recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Mar 2026
- Primary completion
- Mar 2027
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of daratumumab in immune thrombocytopenia (ITP), sponsored by Institute of Hematology and Blood Diseases Hospital. Started Mar 2026; status: recruiting.
02
Drugs
daratumumab
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT07362199.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07362199.